GPRC5DxCD3双特异性抗体talquetamab在多发性骨髓瘤中的临床前活性及应答决定因素
本文为临床前研究,评估GPRC5DxCD3双特异性抗体talquetamab在多发性骨髓瘤中的活性及应答决定因素。talquetamab在健康供者及经治患者T细胞存在下有效杀伤GPRC5D+骨髓瘤细胞系,并在45例患者骨髓样本中显示强效抗骨髓瘤活性,包括高危细胞遗传学异常者。GPRC5D高表达及高效靶比与更佳杀伤相关,而PD-1或HLA-DR阳性T细胞比例增高、调节性T细胞计数升高及骨髓基质细胞直接接触则削弱疗效。
要点
- talquetamab在45例患者骨髓样本中显示强效抗骨髓瘤活性,包括高危细胞遗传学异常者。
- GPRC5D高表达及高效靶比与更佳talquetamab介导的骨髓瘤细胞溶解相关。
- PD-1或HLA-DR阳性T细胞比例增高、调节性T细胞计数升高及骨髓基质细胞接触与杀伤不佳相关。
核心结论
- GPRC5DxCD3双特异性抗体talquetamab是有前景的新型抗骨髓瘤药物。
- 临床前结果为复发/难治性多发性骨髓瘤中正在进行的talquetamab研究提供依据。
研究设计与样本
- 临床前研究,使用GPRC5D+骨髓瘤细胞系及45例患者骨髓样本。
- 效应细胞来自健康供者或经重度预处理的多发性骨髓瘤患者T细胞。
主要发现
- talquetamab在健康供者或经治患者T细胞存在下有效杀伤GPRC5D+骨髓瘤细胞系。
- talquetamab在45例患者骨髓样本中显示强效抗骨髓瘤活性,包括高危细胞遗传学异常者。
- 对新诊断、达雷妥尤单抗未治复发/难治(中位既往3线)及达雷妥尤单抗难治(中位既往6线)患者的骨髓瘤细胞杀伤无差异。
- 肿瘤细胞溶解伴随T细胞活化、脱颗粒及促炎细胞因子产生。
- GPRC5D高表达及高效靶比与改善的talquetamab介导骨髓瘤细胞溶解相关;PD-1或HLA-DR阳性T细胞比例增高及调节性T细胞计数升高与次优杀伤相关。
关键数值与推荐
- 在细胞系实验中,向效应细胞加入调节性T细胞降低骨髓瘤细胞溶解。
- 与骨髓基质细胞直接接触也削弱talquetamab疗效。
- 与达雷妥尤单抗或泊马度胺联合以相加方式增强talquetamab介导的原代骨髓瘤细胞溶解。
临床怎么用
- talquetamab在复发/难治性多发性骨髓瘤中具有临床前抗骨髓瘤活性,支持进一步临床开发。
- GPRC5D表达水平、效应靶比、T细胞表型及调节性T细胞计数可能影响talquetamab疗效。
- 与达雷妥尤单抗或泊马度胺联合可能增强talquetamab的骨髓瘤细胞杀伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic strategies. The novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, effectively kills GPRC5D+ MM cell lines in the presence of T cells from both healthy donors or heavily pretreated MM patients. In addition, talquetamab has potent anti-MM activity in bone marrow (BM) samples from 45 patients, including those with high-risk cytogenetic aberrations. There was no difference in talquetamab-mediated killing of MM cells from newly diagnosed, daratumumab-naïve relapsed/refractory (median of 3 prior therapies), and daratumumab-refractory (median of 6 prior therapies) MM patients. Tumor cell lysis was accompanied by T-cell activation and degranulation, as well as production of pro-inflammatory cytokines. High levels of GPRC5D and high effector:target ratio were associated with improved talquetamab-mediated lysis of MM cells, whereas an increased proportion of T cells expressing PD-1 or HLA-DR, and elevated regulatory T-cell (Treg) counts were associated with suboptimal killing. In cell line experiments, addition of Tregs to effector cells decreased MM cell lysis. Direct contact with bone marrow stromal cells also impaired the efficacy of talquetamab. Combination therapy with daratumumab or pomalidomide enhanced talquetamab-mediated lysis of primary MM cells in an additive fashion. In conclusion, we show that the GPRC5D-targeting T-cell redirecting bispecific antibody talquetamab is a promising novel antimyeloma agent. These results provide the preclinical rationale for ongoing studies with talquetamab in relapsed/refractory MM.
引用
- Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021. PMID: 33890981. doi:10.1182/bloodadvances.2020003805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。